Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Gene | ERBB4 |
| Variant | A17V |
| Impact List | missense |
| Protein Effect | no effect - predicted |
| Gene Variant Descriptions | ERBB4 A17V lies within the signal peptide region of the Erbb4 protein (UniProt.org). A17V results in basal level and ligand-dependent phosphorylation of Erbb4 and downstream signaling comparable to wild-type protein, and is not transforming in culture (PMID: 33323455), and therefore, is predicted to have no effect on Erbb4 protein function. |
| Associated Drug Resistance | |
| Category Variants Paths |
ERBB4 mutant ERBB4 A17V |
| Transcript | NM_005235.3 |
| gDNA | chr2:g.212538481G>A |
| cDNA | c.50C>T |
| Protein | p.A17V |
| Source Database | RefSeq |
| Genome Build | GRCh38/hg38 |
| Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
|---|---|---|---|---|---|
| NM_005235.2 | chr2:g.212538481G>A | c.50C>T | p.A17V | RefSeq | GRCh38/hg38 |
| XM_006712364.3 | chr2:g.212538481G>A | c.50C>T | p.A17V | RefSeq | GRCh38/hg38 |
| NM_001042599.1 | chr2:g.212538481G>A | c.50C>T | p.A17V | RefSeq | GRCh38/hg38 |
| XM_017003581.3 | chr2:g.212538481G>A | c.50C>T | p.A17V | RefSeq | GRCh38/hg38 |
| XM_017003577.2 | chr2:g.212538481G>A | c.50C>T | p.A17V | RefSeq | GRCh38/hg38 |
| XM_006712364.4 | chr2:g.212538481G>A | c.50C>T | p.A17V | RefSeq | GRCh38/hg38 |
| XM_005246376.3 | chr2:g.212538481G>A | c.50C>T | p.A17V | RefSeq | GRCh38/hg38 |
| XM_017003580.2 | chr2:g.212538481G>A | c.50C>T | p.A17V | RefSeq | GRCh38/hg38 |
| XM_017003579.2 | chr2:g.212538481G>A | c.50C>T | p.A17V | RefSeq | GRCh38/hg38 |
| XM_005246377.3 | chr2:g.212538481G>A | c.50C>T | p.A17V | RefSeq | GRCh38/hg38 |
| XM_017003578.3 | chr2:g.212538481G>A | c.50C>T | p.A17V | RefSeq | GRCh38/hg38 |
| XM_017003579.3 | chr2:g.212538481G>A | c.50C>T | p.A17V | RefSeq | GRCh38/hg38 |
| XM_017003577.3 | chr2:g.212538481G>A | c.50C>T | p.A17V | RefSeq | GRCh38/hg38 |
| XM_017003581.2 | chr2:g.212538481G>A | c.50C>T | p.A17V | RefSeq | GRCh38/hg38 |
| NM_001042599.1 | chr2:g.212538481G>A | c.50C>T | p.A17V | RefSeq | GRCh38/hg38 |
| NM_005235.3 | chr2:g.212538481G>A | c.50C>T | p.A17V | RefSeq | GRCh38/hg38 |
| XM_017003578.2 | chr2:g.212538481G>A | c.50C>T | p.A17V | RefSeq | GRCh38/hg38 |
| XM_005246376.4 | chr2:g.212538481G>A | c.50C>T | p.A17V | RefSeq | GRCh38/hg38 |
| XM_017003580.3 | chr2:g.212538481G>A | c.50C>T | p.A17V | RefSeq | GRCh38/hg38 |
| XM_005246377.4 | chr2:g.212538481G>A | c.50C>T | p.A17V | RefSeq | GRCh38/hg38 |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| ERBB4 mutant | lung squamous cell carcinoma | predicted - sensitive | Afatinib | Phase III | Actionable | In a Phase III trial (LUX-Lung 8), secondary analysis demonstrated favorable outcomes with Gilotrif (afatinib) treatment compared to Tarceva (erlotinib) in lung squamous cell carcinoma patients with ERBB (HER) family mutations, and ERBB4 (HER4) mutations predicted an OS (HR=0.22) and PFS (HR=0.21) benefit for Gilotrif (afatinib) over Tarceva (erlotinib) treatment (PMID: 29902295; NCT01523587). | 29902295 |